Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors

Clin Lung Cancer. 2021 Mar 16:S1525-7304(21)00056-5. doi: 10.1016/j.cllc.2021.03.004. Online ahead of print.ABSTRACTThis review covers the importance of local consolidative therapy (LCT) in patients with epidermal growth factor receptor (EGFR) mutation-positive with oligometastatic and oligoprogressive non-small-cell lung cancer (NSCLC). With the advent of third-generation EGFR tyrosine kinase inhibitors, a more updated review is necessary. We review the efficacy of LCT, pathophysiological background, and treatment modalities other than radiotherapy. In addition, we also discussed when and how LCT should be applied to patients with oligometastatic and oligoprogressive NSCLC.PMID:33849807 | DOI:10.1016/j.cllc.2021.03.004
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research